Key Points
- Insider sale: SVP Marshall Stanton sold 15,276 shares of AORT on Nov. 20 at an average of $44.18 for $674,893.68, cutting his stake by 25.45% to 44,753 shares (≈$1.98M) as disclosed in an SEC filing.
- Quarterly results: Artivion reported $0.16 EPS vs. $0.14 expected and revenue of $113.39M (up 18.9% YoY), while the stock trades near its 52-week high and the company has a market cap of about $2.17B.
- Analyst sentiment and ownership: The consensus is a "Moderate Buy" with an average price target of $49.11 (7 Buys, 1 Hold, 1 Sell), and institutional investors hold roughly 86.37% of the shares.
Artivion, Inc. (NYSE:AORT - Get Free Report) SVP Marshall Stanton sold 15,276 shares of the stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $44.18, for a total value of $674,893.68. Following the sale, the senior vice president owned 44,753 shares in the company, valued at approximately $1,977,187.54. This trade represents a 25.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Artivion Stock Performance
NYSE AORT opened at $45.81 on Tuesday. Artivion, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $48.04. The stock has a market cap of $2.17 billion, a price-to-earnings ratio of -109.07 and a beta of 1.65. The business has a fifty day moving average of $43.09 and a 200-day moving average of $37.16. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52.
Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.16 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.02. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The business had revenue of $113.39 million for the quarter, compared to analyst estimates of $110.71 million. The company's revenue was up 18.9% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. As a group, analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on AORT. Weiss Ratings reiterated a "sell (d-)" rating on shares of Artivion in a report on Wednesday, October 8th. LADENBURG THALM/SH SH cut shares of Artivion from a "buy" rating to a "neutral" rating and lifted their target price for the stock from $32.00 to $38.80 in a research note on Wednesday, August 13th. Oppenheimer reiterated an "outperform" rating and issued a $50.00 price target on shares of Artivion in a report on Friday, November 7th. Stifel Nicolaus raised their price objective on Artivion from $40.00 to $46.00 and gave the stock a "buy" rating in a report on Monday, September 29th. Finally, Canaccord Genuity Group lifted their price objective on Artivion from $50.00 to $51.00 and gave the company a "buy" rating in a research report on Friday, November 7th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $49.11.
Check Out Our Latest Analysis on Artivion
Hedge Funds Weigh In On Artivion
Hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Artivion during the 3rd quarter worth $27,000. Aster Capital Management DIFC Ltd boosted its holdings in Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company's stock valued at $27,000 after acquiring an additional 519 shares during the last quarter. Smartleaf Asset Management LLC grew its position in Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock valued at $52,000 after acquiring an additional 538 shares during the period. State of Wyoming purchased a new stake in Artivion during the third quarter valued at about $80,000. Finally, Quadrant Capital Group LLC acquired a new stake in Artivion during the third quarter worth about $92,000. Institutional investors and hedge funds own 86.37% of the company's stock.
About Artivion
(
Get Free Report)
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
